Shingles Vaccination in 2026: Shingrix's Proven Benefits
Updated January 2026 with the latest research from 2024 –2025 studies Shingrix: A New Era in Shingles Prevention and Systemic Health The landscape of adult immunization shifted dramatically in 2017 with the introduction of a powerhouse vaccine that redefined expectations for efficacy. Beyond simply preventing painful skin eruptions, recent clinical insights suggest Shingrix® may offer broader protective benefits for both neurological and cardiovascular health: A Leap in Efficacy : Licensed by the FDA in October 2017 for adults 50 and older, Shingrix® boasts an impressive efficacy rate exceeding 90%, vastly outperforming its predecessor. [4] The Gold Standard Protocol : To ensure maximum immunity, the CDC advises a two-dose series, with the second shot administered two to six months after the first. Official Preference : In late 2017, the ACIP officially designated Shingrix® as the preferred vaccine, even for those who had already been immunized with the older version. Phasing Out the ...